Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Abstract Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes include...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Keith W. Pratz, Panayiotis Panayiotidis, Christian Recher, Xudong Wei, Brian A. Jonas, Pau Montesinos, Vladimir Ivanov, Andre C. Schuh, Courtney D. DiNardo, Jan Novak, Vlatko Pejsa, Don Stevens, Su-Peng Yeh, Inho Kim, Mehmet Turgut, Nicola Fracchiolla, Kazuhito Yamamoto, Yishai Ofran, Andrew H. Wei, Cat N. Bui, Katy Benjamin, Rajesh Kamalakar, Jalaja Potluri, Wellington Mendes, Jacob Devine, Walter Fiedler
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group 2022-04-01
Reeks:Blood Cancer Journal
Online toegang:https://doi.org/10.1038/s41408-022-00668-8
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items